Drug intelligence / Profile preview

CRD-799

Development stage: Unknown
Lead developer: Cardurion Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

CRD-799 is an investigational small molecule therapeutic being developed by Cardurion Pharmaceuticals. It is designed as a potent and selective inhibitor of Calcium/Calmodulin-dependent Protein Kinase II (CaMKII), a signaling protein that plays a critical role in the regulation of calcium handling and electrical activity within the heart. Chronic overactivation of CaMKII is associated with various cardiovascular pathologies, including heart failure and arrhythmias. By inhibiting CaMKII, CRD-799 aims to restore normal calcium homeostasis and improve cardiac function, potentially offering a novel treatment approach for patients with heart failure and other calcium-driven cardiac conditions.

Targets

CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)

Beyond the preview

Go deeper on CRD-799.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRD-799.

Explore the full profile